Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Sensitive Test Enables Early Diagnosis of Rheumatoid Arthritis

By Labmedica International staff writers
Posted on 14 Dec 2011
Print article
A highly sensitive and specific laboratory test enables the early diagnosis of rheumatoid arthritis (RA), which in turn allows for successful treatment of this autoimmune disease.

The new Anti-CCP hs (high sensitive) test is the most recent development in the area of anticitrullinated peptide antibody (ACPA) testing. This innovative enzyme immunoassay combines the advantages of mutated citrullinated vimentin (MCV) antibody detection (anti-MCV), with the power of modern peptide synthesis. It an effective tool for the rapid and precise routine diagnosis of suspected RA and the diagnosis of early rheumatoid arthritis.

In combination with medical history, clinical observations, and imaging techniques, serological tests like Anti-CCP hs are the basis for early diagnosis of RA. Early diagnosis is critical to patient outcomes because early, effective treatment can avert damage to the joints and maintain their function.

Orgentec Diagnostika (Mainz, Germany) developed the Anti-CCP hs test; it also develops and markets test systems for autoimmune diagnostics and serological tests for infectious disease. Orgentec has developed numerous highly specific ELISA test systems, immunoblot and immunofluorescence tests, the Alegria random access analyzer, and the rheumachec rapid test.

Related Links:
Orgentec Diagnostika


Print article
Abbott Diagnostics

Channels

Industry News

view channel

Global In Vitro Diagnostic Test Market Worth USD 60 Billion

The global in vitro diagnostic (IVD) test market is currently worth USD 60.5 billion and will continue to grow, though a moderate and gradual change is likely to be witnessed over the next five to ten years, as more opportunities are created in novel tests and growing regions, while the traditional categories and reliable... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.